2023
Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study
Zhan H, Fineberg S, Podany P, Zeng J, Wang Y, Harigopal M, Singh K. Pathological response in mucinous carcinoma of breast after neoadjuvant therapy - a multi-institutional study. Human Pathology 2023, 142: 15-19. PMID: 37972873, DOI: 10.1016/j.humpath.2023.10.002.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyResidual tumour cellularityNeoadjuvant chemotherapyNeoadjuvant therapyMucinous carcinomaPathologic responseEndocrine therapyPathological responseMucin poolsBreast cancerEstrogen receptorTumor cellularityAcellular mucin poolsFavorable histologic subtypePreoperative adjuvant therapyRetrospective cohort studyComplete pathologic responseInvasive breast cancerNET groupMulti-institutional studyNeoadjuvant HER2Adjuvant therapyMC patientsCohort studyPathologic review
2018
Breast cancer histopathology is predictive of low‐risk Oncotype Dx recurrence score
Wilson PC, Chagpar AB, Cicek AF, Bossuyt V, Buza N, Mougalian S, Killelea BK, Patel N, Harigopal M. Breast cancer histopathology is predictive of low‐risk Oncotype Dx recurrence score. The Breast Journal 2018, 24: 976-980. PMID: 30230117, DOI: 10.1111/tbj.13117.Peer-Reviewed Original ResearchConceptsLymph node-negative patientsNode-negative patientsOncotype DX testingInvasive carcinomaLow-grade invasive carcinomasHistologic subtypeOncotype DXRecurrence scoreEstrogen receptorHigh riskAJCC Breast Cancer Staging SystemBreast cancer staging systemOncotype DX recurrence scoreFavorable histologic subtypeOncotype recurrence scoreSimple multivariable modelsCancer (AJCC) staging systemRisk of recurrenceDX recurrence scoreOnly significant predictorExcellent prognosisIntermediate riskDuctal carcinomaHistologic gradeHistologic predictors